Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Metagenomi Therapeutics, Inc. (MGX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalisation of $44.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.13 to $3.95. This page covers its latest market performance, valuation, price trends and company information.
$44.95M | |
$1.16 | |
$12.74 | |
$1.13 | |
$1.16 | |
54.54K | |
165.54K | |
-- | |
$3.95 | |
$1.13 | |
-- | |
-- |
Metagenomi Therapeutics, Inc. (MGX) is currently trading at $1.17 as of 2026-09-16 14:40:00, up 0.43% ($0.01) from the previous close of $1.16
During today's regular trading session, MGX has traded between $1.13 and $12.74, with a trading volume of 54.54K shares. The current price is near the lower end of today's range.
Over the past seven days, Metagenomi Therapeutics, Inc. (MGX) moved from $1.17 to $1.17, representing a decline of 0.43% ($0.00).
The stock traded between $1.13 and $1.22 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 191.48 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.3%
MGX is currently trading at $1.17, placing it 1.3% of the way from its 52-week low of $1.13 to its 52-week high of $3.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Metagenomi Therapeutics, Inc. (MGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.